ExcellGene and Cytena team up to optimize workflows for mAb and therapeutic protein manufacturing

By Jane Byrne

- Last updated on GMT

© GettyImages/Blackholy
© GettyImages/Blackholy

Related tags CDMO Biologics Cell line recombinant protein

ExcellGene SA, a Swiss biologics focused CDMO, has established a collaboration agreement with German biological cell instrument developer, Cytena.

The companies intend to streamline cell line development workflows for monoclonal antibody (mAb) and complex therapeutic protein manufacturing.

Headquartered in Monthey, Switzerland, and formed as a spin-off from the Swiss Federal Institute of Technology, ExcellGene works with industry players focused on vaccines, diagnostics, and drug development; it provides recombinant proteins, high-yielding CHO and HEK-293 cell-based manufacturing services.

Cell line development

As part of the alliance, that contract development and manufacturing organization (CDMO) is giving Cytena access to its CHOExpress system, which it said is a proven, high-yield mammalian host cell line for large-scale manufacturing of therapeutic proteins.

Cytena will establish workflows on its new, next generation automated workstation for cell line development (CLD), called C. Station, which is designed to reduce timelines, eliminate contamination, and improve cell viability.

Dr Julian Riba, CEO of Cytena, said the tie-up would allow the company to establish more efficient protocols for stable CHO cell line development (CLD) on its new platform, with the idea of making the production of biotherapeutic proteins “faster, safer, and more affordable.”

Professor Florian Wurm, CSO and cofounder of ExcellGene, said: “Having worked with several Cytena cell handling tools from the earliest days of their offerings, we were pleased to see innovative and well thought-through instrumentation, including a flow of innovative concepts aiming at addressing a major bottleneck in the development of biologics using cultivated animal cells: the proof of monoclonality."

He said the collaborative effort with Cytena would solidify the CDMO’s lead in science-based cell line and process development for pharma customers.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more